Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SRPT

Sarepta Therapeutics Inc

Dec 13 • 04:00PM ET

123.71

Dollar change -0.76
Percentage change -0.61	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: IJH VTI VB VXF XBI VBK MDY IBB IWP IJK

Scroll to Statements

Index	-	P/E	102.77	EPS (ttm)	1.20	Insider Own	6.91%	Shs Outstand	95.49M	Perf Week	-3.48%
Market Cap	11.74B	Forward P/E	11.17	EPS next Y	11.08	Insider Trans	-0.32%	Shs Float	88.92M	Perf Month	9.98%
Income	121.84M	PEG	-	EPS next Q	1.54	Inst Own	89.96%	Short Float	6.54%	Perf Quarter	-0.50%
Sales	1.64B	P/S	7.16	EPS this Y	138.37%	Inst Trans	-2.35%	Short Ratio	6.05	Perf Half Y	0.71%
Book/sh	12.79	P/B	9.67	EPS next Y	397.60%	ROA	3.63%	Short Interest	5.82M	Perf Year	34.31%
Cash/sh	12.62	P/C	9.80	EPS next 5Y	-	ROE	12.27%	52W Range	87.00 - 173.25	Perf YTD	28.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.21%	ROI	4.82%	52W High	-28.59%	Beta	0.75
Dividend TTM	-	Quick Ratio	3.03	Sales past 5Y	32.89%	Gross Margin	83.56%	52W Low	42.20%	ATR (14)	4.46
Dividend Ex-Date	-	Current Ratio	3.84	EPS Y/Y TTM	116.50%	Oper. Margin	4.94%	RSI (14)	50.15	Volatility	2.68% 3.84%
Employees	1314	Debt/Eq	1.14	Sales Y/Y TTM	48.45%	Profit Margin	7.43%	Recom	1.36	Target Price	185.20
Option/Short	Yes / Yes	LT Debt/Eq	1.07	EPS Q/Q	173.55%	Payout	-	Rel Volume	0.66	Prev Close	124.47
Sales Surprise	14.74%	EPS Surprise	670.47%	Sales Q/Q	40.79%	Earnings	Nov 06 AMC	Avg Volume	961.60K	Price	123.71
SMA20	1.73%	SMA50	0.77%	SMA200	-4.61%	Trades		Volume	637,886	Change	-0.61%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-24	Reiterated	Needham	Buy	$205 → $202
Nov-25-24	Initiated	H.C. Wainwright	Sell	$80
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$152 → $167
Oct-21-24	Initiated	Jefferies	Buy	$165
Oct-10-24	Resumed	Raymond James	Outperform	$150
Jul-29-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$182
Jun-26-24	Downgrade	Citigroup	Buy → Neutral	$172 → $176
May-31-24	Initiated	Piper Sandler	Overweight	$157
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$157 → $142
May-14-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$170
Dec-13-23	Resumed	Citigroup	Buy	$113
Dec-12-23	Initiated	Deutsche Bank	Buy	$109
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$166 → $40
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line	$139
Apr-26-23	Initiated	SMBC Nikko	Outperform	$185
Apr-04-23	Initiated	Citigroup	Buy	$179
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$141 → $187

Show Previous Ratings

Dec-14-24 09:16PM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
Dec-13-24 09:55AM	Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? (Zacks)
Dec-06-24 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report? (Zacks)
Nov-30-24 06:00AM	Arrowhead price target lowered to $24 from $27 at Bernstein (TipRanks)
Nov-29-24 04:10PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:15AM	Loading…
Nov-28-24 08:15AM	Sarepta price target lowered to $202 from $205 at Needham (TipRanks)
Nov-27-24 09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet (Zacks) +5.70%
07:21AM	Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments (TipRanks)
07:20AM	Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board (TipRanks)
06:00AM	Sarepta rebuilds drug pipeline with Arrowhead deal (BioPharma Dive)
04:33AM	Arrowhead and Sarepta link for rare genetic disease treatments (Pharmaceutical Technology)
Nov-26-24 05:18PM	Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal (Investor's Business Daily) +13.82%
04:05PM	Arrowhead Pharma, Sarepta TX ink new gene therapy deal (Yahoo Finance Video)
09:06AM	Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta (Investor's Business Daily)
07:00AM	Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs (Business Wire)
07:00AM	Loading…
07:00AM	Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs (Business Wire)
Nov-15-24 12:26PM	Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now (Insider Monkey)
Nov-12-24 06:56AM	Sarepta recent weakness brings buying opportunity, says JPMorgan (TipRanks)
Nov-08-24 06:57AM	Sarepta price target lowered to $193 from $200 at Baird (TipRanks)
Nov-07-24 06:01AM	Sarepta scraps a Duchenne drug as gene therapy sales rise (BioPharma Dive) -5.90%
04:00AM	Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript (Motley Fool)
02:20AM	Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 06:30PM	Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:22PM	Sarepta Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments (Business Wire)
Oct-31-24 04:10PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-24 09:07AM	Sarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You Richer (Insider Monkey)
Oct-23-24 08:30AM	Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results (Business Wire)
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-17-24 09:53AM	2 High-Flying Growth Stocks With Massive Upside Potential (Motley Fool)
04:02PM	Loading…
Oct-16-24 04:02PM	Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-03-24 08:15AM	Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics (Motley Fool)
Sep-30-24 04:39PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:38PM	Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:30AM	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress (Business Wire)
Sep-21-24 10:10AM	Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity (Insider Monkey)
Sep-19-24 08:30AM	Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options (Zacks)
Sep-16-24 08:30AM	Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors (Business Wire)
Sep-14-24 07:27PM	Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 06:45AM	These 2 Biotech Stocks Are Set to Soar (Motley Fool)
Sep-08-24 02:00AM	Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar (Insider Monkey)
Sep-06-24 11:31AM	Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report? (Zacks)
Sep-05-24 09:00AM	Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year (Business Wire)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga)
Aug-30-24 04:10PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:53AM	DMD clinical studies evolve with emphasis on building designs around relevant endpoints (Clinical Trials Arena)
08:30AM	Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 02:30PM	Heard Writers Pick Their Favorite and Least-Favorite Stocks (The Wall Street Journal)
Aug-19-24 07:00AM	A $3 Million Gene-Therapy Maker at a Bargain Price (The Wall Street Journal)
Aug-12-24 09:30AM	2 Biotech Stocks to Buy Hand Over Fist in August (Motley Fool)
Aug-09-24 04:17PM	How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics (Investor's Business Daily) -8.11%
09:35AM	Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT) (Zacks)
Aug-08-24 01:36PM	Q2 2024 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:50AM	Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak (Zacks)
12:30AM	Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-07-24 06:00PM	Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics (Zacks)
04:28PM	Sarepta Therapeutics falls on revenue miss, weak outlook (Investing.com)
04:17PM	Sarepta Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments (Business Wire)
Aug-05-24 12:00PM	What Makes Sarepta Therapeutics (SRPT) a New Buy Stock (Zacks)
Aug-01-24 10:01AM	Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory (Insider Monkey)
Jul-31-24 04:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-24 07:00AM	Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results (Business Wire)
Jul-21-24 06:59AM	This market expert warns real estate woes may not be limited to commercial 3 'idiosyncratic' stocks he likes (Moneywise)
Jul-19-24 09:55AM	Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade (Zacks)
Jul-17-24 08:00AM	Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives (GlobeNewswire)
Jul-16-24 12:00PM	What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-08-24 12:04PM	Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD (Zacks)
Jul-06-24 08:00AM	After a Big Win, Is Sarepta Therapeutics Stock a Buy? (Motley Fool)
Jul-04-24 06:35AM	Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? (Motley Fool)
Jul-03-24 10:05AM	1 Soaring Growth Stock to Buy and Hold for 10 Years (Motley Fool)
Jun-28-24 06:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-24 10:06AM	Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. (Motley Fool)
03:45AM	Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Jun-24-24 02:55PM	Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval (Investor's Business Daily)
03:49AM	Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock? (Zacks)
Jun-21-24 05:25PM	What next for gas prices, how the S&P 500 can reach 6,000: Market Domination (Yahoo Finance Video) +30.14%
05:05PM	S&P 500 Gains and Losses Today: Index Edges Lower as AI-Fueled Rally Loses Steam (Investopedia)
04:28PM	Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy (Investor's Business Daily)
04:23PM	These Stocks Moved the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More (Barrons.com)
02:39PM	These Stocks Are Moving the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More (Barrons.com)
01:53PM	Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment (The Wall Street Journal)
01:00PM	Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More (Investopedia)
12:58PM	US indexes open mixed, pharmaceutical stocks climb: Morning Brief (Yahoo Finance Video)
12:48PM	Sarepta Therapeutics, Ryan Specialty rise; Autodesk, Trump Media fall, Friday, 6/21/2024 (Associated Press)
12:29PM	Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone (Investor's Business Daily)
12:14PM	Stocks to Watch Friday: Nvidia, Micron, Sarepta, CarMax (The Wall Street Journal)
11:24AM	FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label (Zacks)
11:09AM	Sarepta Gains as FDA Official Overrules Staff to Approve Therapy (Bloomberg)
11:00AM	Gene Therapy Developer Sarepta's Stock Soars on Best-Case FDA Decision (The Wall Street Journal)
10:42AM	Sarepta Stock Surges on Expanded Elevidys Approval. Its a Best-Case Scenario for Shares. (Barrons.com)
09:32AM	Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost (InvestorPlace)
09:31AM	Sarepta surges on expanded approval of muscular dystrophy drug (Yahoo Finance Video)
09:14AM	Nvidia, triple-witching, biotech stock gains: 3 Things (Yahoo Finance Video)
08:42AM	Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug (Investopedia)
07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:34AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:40AM	Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy (Investor's Business Daily)
Jun-20-24 05:02PM	Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above (Business Wire) +5.09%
02:13PM	Sarepta Therapeutics surges 36% after-hours following expanded FDA approval (Investing.com)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Proposed Sale	124.80	10,500	1,310,400		Dec 12 05:06 PM
Boor Kathryn Jean	Director	Dec 05 '24	Sale	125.55	1,636	205,400	5,880	Dec 06 08:00 PM
Boor Kathryn Jean	Director	Dec 05 '24	Proposed Sale	125.55	1,636	205,400		Dec 05 04:18 PM
Estepan Ian Michael	Chief Financial Officer	Aug 30 '24	Sale	137.36	5,985	822,100	33,946	Sep 03 08:00 PM
Estepan Ian Michael	Officer	Aug 30 '24	Proposed Sale	137.37	5,985	822,130		Aug 30 05:03 PM
Chambers Michael Andrew	Director	Aug 16 '24	Buy	133.80	37,038	4,955,728	284,034	Aug 20 08:00 AM
BEHRENS M KATHLEEN	Director	Jul 03 '24	Option Exercise	13.90	15,000	208,500	191,839	Jul 08 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Option Exercise	62.77	23,500	1,475,095	56,086	Jun 25 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Sale	161.61	38,957	6,296,029	17,129	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 24 '24	Sale	163.08	7,859	1,281,621	21,261	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 25 '24	Sale	163.23	3,898	636,271	17,363	Jun 25 08:00 PM
Murray Dallan	Chief Customer Officer	May 02 '24	Sale	140.00	3,635	508,900	18,125	May 06 08:09 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Option Exercise	13.90	15,000	208,500	37,840	Mar 11 08:02 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Sale	123.25	15,000	1,848,795	22,840	Mar 11 08:02 PM
Boor Kathryn Jean	Director	Mar 11 '24	Sale	122.93	761	93,550	7,516	Mar 11 08:00 PM
Mayo Stephen	Director	Mar 05 '24	Sale	122.96	3,135	385,480	6,621	Mar 06 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Mar 01 '24	Sale	128.84	2,000	257,676	26,836	Mar 05 08:00 PM
Estepan Ian Michael	Chief Financial Officer	Mar 01 '24	Sale	128.30	1,200	153,960	39,114	Mar 05 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Mar 01 '24	Sale	125.34	2,000	250,680	31,827	Mar 05 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience